Nkarta, Inc. (NASDAQ:NKTX) Stock Position Increased by Catalina Capital Group LLC

Catalina Capital Group LLC increased its position in Nkarta, Inc. (NASDAQ:NKTX) by 57.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 18,818 shares of the company’s stock after buying an additional 6,867 shares during the quarter. Catalina Capital Group LLC’s holdings in Nkarta were worth $47,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. JPMorgan Chase & Co. raised its holdings in shares of Nkarta by 252.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,063,362 shares of the company’s stock worth $4,806,000 after purchasing an additional 761,349 shares in the last quarter. Wasatch Advisors LP grew its position in Nkarta by 31.7% in the third quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after buying an additional 442,125 shares during the last quarter. AQR Capital Management LLC bought a new position in shares of Nkarta in the second quarter valued at $938,000. Barclays PLC lifted its position in shares of Nkarta by 161.4% during the 3rd quarter. Barclays PLC now owns 232,566 shares of the company’s stock valued at $1,051,000 after acquiring an additional 143,608 shares during the last quarter. Finally, FMR LLC lifted its position in shares of Nkarta by 97.1% during the 3rd quarter. FMR LLC now owns 133,149 shares of the company’s stock valued at $602,000 after acquiring an additional 65,600 shares during the last quarter. Institutional investors own 80.54% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on NKTX. Mizuho cut their target price on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. RODMAN&RENSHAW upgraded Nkarta to a “strong-buy” rating in a report on Wednesday, October 9th. Needham & Company LLC reduced their price objective on shares of Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Rodman & Renshaw started coverage on shares of Nkarta in a research report on Wednesday, October 9th. They issued a “buy” rating and a $14.00 target price on the stock. Finally, HC Wainwright reduced their price target on shares of Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Nkarta presently has an average rating of “Buy” and a consensus target price of $15.00.

Nkarta Price Performance

NASDAQ NKTX opened at $2.26 on Wednesday. Nkarta, Inc. has a 52-week low of $2.08 and a 52-week high of $16.24. The firm has a market capitalization of $159.49 million, a price-to-earnings ratio of -1.20 and a beta of 0.85. The company has a 50 day simple moving average of $2.46 and a 200-day simple moving average of $3.87.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.02). On average, analysts predict that Nkarta, Inc. will post -1.68 EPS for the current year.

Insider Activity at Nkarta

In other Nkarta news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total value of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 8.70% of the stock is currently owned by company insiders.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.